Elkem ASA: Minutes from Extraordinary General Meeting

Elkem entered a Share Purchase Agreement (announced 13 Feb 2026) to sell the majority (>50%) of its Silicones division to Bluestar, to be settled by transferring all Elkem shares held by Bluestar Elkem International Co. Ltd. S.A. An extraordinary general meeting on 9 Mar 2026 was called to vote on approval of the transaction and to resolve related share redemption matters. The transaction is a material M&A that will alter Elkem’s asset and ownership structure and could meaningfully affect its capital structure and shareholder base pending shareholder approval.

Analysis

The deal dynamics will likely do more than move ownership — they materially change Elkem’s free float and optionality profile. A successful execution and subsequent redemption reduces public float and creates immediate capacity for capital returns (buyback/special dividend) or accelerated deleveraging; those mechanically lift EPS and reduce required liquidity buffers, which investors often misprice as a permanent operational uplift rather than a one‑time re‑rating catalyst.

Second‑order supply effects matter: Bluestar’s integration incentives are to optimize global silicones flows, which will shift volumes toward lower‑cost Chinese capacity over 12–36 months and put margin pressure on non‑integrated Western silicones peers that can’t flex capacity rapidly. That dynamic favors specialty downstream players with sticky contract coverage while making commodity silicones producers vulnerable to margin compression and potential capacity consolidation.

Key risks are binary and time‑staged: shareholder/EGM outcomes and antitrust clearances are week‑to‑quarter catalysts, while integration and price effects play out over 6–24 months. A failed vote or adverse regulator opens a clear downside path (equity gap and headline risk); conversely, approval plus a committed redemption/buyback creates an asymmetric, event‑driven upside that trades well into the 12‑month window if paired with active position sizing and cheap put protection.

Key Decisions for Investors

• Event‑driven long Elkem (ELK.OL): buy post‑EGM approval with a 6–12 month horizon. Size to 2–4% NAV, target 20–35% upside driven by float reduction + potential buyback; protect with a 6–12 month 10–15% OTM put (or 5–8% notional hedge) to cap downside to ~12–15% if the deal is reversed or regulators impose conditions.
• Pair trade — long ELK.OL / short WCH.DE (Wacker Chemie): 1:1 notional for 6–18 months. Rationale: Elkem benefits from simplification and capital returns while Wacker is more exposed to near‑term price competition from Bluestar’s China scale. Target asymmetric payoff ~2:1 if re‑rating + margin pressure materialize; cut pair if silicones spot spreads tighten more than 15% and both names move together.
• Credit arb watchlist: be ready to buy Elkem senior paper if spreads widen >100bp on deal uncertainty (target capture 5–8% YTM over 1–3 years). Deployment conditional on clear balance‑sheet read and covenant terms; downside is limited if buyback/redeem expectations persist but wideners create attractive yield cushion.
• Catalyst hedge: enter a small (~0.5–1% NAV) long‑gamma/options position that benefits from approval headlines (near‑dated calls on ELK.OL around EGM) while capping drawdown — removes political/EGM headline risk and monetizes probable short‑term volatility spikes.